Literature DB >> 22843168

The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.

Ahmad Husari1, Atallah Beydoun, Amein Sheik Ammar, Joseph E Maakaron, Ali Taher.   

Abstract

We report an 85-year-old male, with history of interstitial pulmonary fibrosis (IPF), who was presented with progressive dyspnea, hypoxia, and anemia of 2 months duration. Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation. His prior anemia workup included a negative upper endoscopy and colonoscopy. Bronchoscopy revealed copious amounts of bloody secretions. The bronchial tree was washed and Dabigatran was discontinued. The patient's medical condition improved and was subsequently discharged home. Our case illustrates the failure of current literature to predict the isolated bronchoalveolar bleed secondary to Dabigatran therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22843168     DOI: 10.1007/s11239-012-0784-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  5 in total

1.  Bleeding risk with dabigatran in the frail elderly.

Authors:  Paul Harper; Laura Young; Eileen Merriman
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

Review 2.  Managing bleeding complications in patients treated with the old and the new anticoagulants.

Authors:  Erica Romualdi; Elena Rancan; Sergio Siragusa; Walter Ageno
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

3.  The use of dabigatran in elderly patients.

Authors:  Matthieu Legrand; Joaquim Mateo; Alice Aribaud; Sixtine Ginisty; Pirayeh Eftekhari; Patrice Tran Ba Huy; Ludovic Drouet; Didier Payen
Journal:  Arch Intern Med       Date:  2011-07-25

Review 4.  Management of atrial fibrillation.

Authors:  Gregory Y H Lip; Hung-Fat Tse
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

5.  A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Authors:  Imre Noth; Kevin J Anstrom; Sara Bristol Calvert; Joao de Andrade; Kevin R Flaherty; Craig Glazer; Robert J Kaner; Mitchell A Olman
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

  5 in total
  5 in total

Review 1.  Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.

Authors:  Julie Kalabalik; Gail B Rattinger; Jesse Sullivan; Malgorzata Slugocki; Antonia Carbone; Anastasia Rivkin
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

2.  Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry.

Authors:  Georgios Tsivgoulis; Christos Krogias; Kara A Sands; Vijay K Sharma; Aristeidis H Katsanos; Konstantinos Vadikolias; Sokratis G Papageorgiou; Ioannis Heliopoulos; Harn Shiue; Athina Mitsoglou; Chrissoula Liantinioti; Dimitrios Athanasiadis; Sotirios Giannopoulos; Charitomeni Piperidou; Konstantinos Voumvourakis; Andrei V Alexandrov
Journal:  Ther Adv Neurol Disord       Date:  2014-05       Impact factor: 6.570

3.  Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.

Authors:  Manabu Hayama; Hideki Inoue; Hiromichi Wada; Tadashi Mio
Journal:  BMJ Case Rep       Date:  2014-02-19

4.  Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Keishi Oda; Hiroshi Ishimoto; Sohsuke Yamada; Hisako Kushima; Hiroshi Ishii; Tomotoshi Imanaga; Tatsuhiko Harada; Yuji Ishimatsu; Nobuhiro Matsumoto; Keisuke Naito; Kazuhiro Yatera; Masamitsu Nakazato; Jun-Ichi Kadota; Kentaro Watanabe; Shigeru Kohno; Hiroshi Mukae
Journal:  Respir Res       Date:  2014-09-01

5.  Interstitial pneumonia caused by dabigatran.

Authors:  Toyoshi Yanagihara; Norio Yamamoto; Yasuaki Kotetsu; Naoki Hamada; Eiji Harada; Kunihiro Suzuki; Kayo Ijichi; Yoshinao Oda; Yoichi Nakanishi
Journal:  Respir Med Case Rep       Date:  2017-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.